Pamidronate inhibits antiapoptotic bcl-2 expression through inhibition of the mevalonate pathway in prostate cancer PC-3 cells

European Journal of Pharmacology

Volumn 641, Issue 1, 2010, Pages 35-40

  Iguchi, Kazuhiro ^a   Tatsuda, Yoshiki ^a   Usui, Shigeyuki ^a   Hirano, Kazuyuki ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Bcl 2; Bisphosphonate; Mevalonate pathway; Pamidronate; Prostate cancer; Rap1

Indexed keywords

GERANYLGERANIOL; GERANYLGERANYL TRANSFERASE INHIBITOR 286; ISOPRENOID; MESSENGER RNA; MEVALONIC ACID; PAMIDRONIC ACID; PROTEIN BCL 2; RAP1 PROTEIN; SMALL INTERFERING RNA; TRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE;

APOPTOSIS; ARTICLE; BIOSYNTHESIS; CELL VIABILITY; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; DRUG EFFECTS; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; PROTEIN PRENYLATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DIPHOSPHONATES; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MEVALONIC ACID; PROSTATIC NEOPLASMS; PROTEIN PRENYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; RAP1 GTP-BINDING PROTEINS; SIGNAL TRANSDUCTION;

EID: 77953812531     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.05.010     Document Type: Article

References (40)

1. Asahi H., Mizokami A., Maeda Y., Komatsu K., Koshida K., Namiki M. Bisphosphonate therapy for hormone refractory prostate cancer with bone metastasis. J. Urol. 2003, 169:281-282.
2. Asahi H., Mizokami A., Miwa S., Keller E.T., Koshida K., Namiki M. Bisphosphonate induces apoptosis and inhibits pro-osteoclastic gene expression in prostate cancer cells. Int. J. Urol. 2006, 13:593-600.
3. Azad N., Vallyathan V., Wang L., Tantishaiyakul V., Stehlik C., Leonard S.S., Rojanasakul Y. S-nitrosylation of Bcl-2 inhibits its ubiquitin-proteasomal degradation. A novel antiapoptotic mechanism that suppresses apoptosis. J. Biol. Chem. 2006, 281:34,124-34,134.
4. Boissier S., Ferreras M., Peyruchaud O., Magnetto S., Ebetino F.H., Colombel M., Delmas P., Delaisse J.M., Clezardin P. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 2000, 60:2949-2954.
5. Bradley D.A., Hussain M. Promising novel cytotoxic agents and combinations in metastatic prostate cancer. Cancer J. 2008, 14:15-19.
6. Colombel M., Symmans F., Gil S., O'Toole K.M., Chopin D., Benson M., Olsson C.A., Korsmeyer S., Buttyan R. Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am. J. Pathol. 1993, 143:390-400.
7. Fabbri F., Brigliadori G., Carloni S., Ulivi P., Vannini I., Tesei A., Silvestrini R., Amadori D., Zoli W. Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line. J. Transl. Med. 2008, 6:43.
8. Fleisch H. Development of bisphosphonates. Breast Cancer Res. 2002, 4:30-34.
9. Fleisch H., Russell R.G., Francis M.D. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 1969, 165:1262-1264.
10. Gnant M., Mlineritsch B., Schippinger W., Luschin-Ebengreuth G., Postlberger S., Menzel C., Jakesz R., Seifert M., Hubalek M., Bjelic-Radisic V., Samonigg H., Tausch C., Eidtmann H., Steger G., Kwasny W., Dubsky P., Fridrik M., Fitzal F., Stierer M., Rucklinger E., Greil R., Marth C. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J. Med. 2009, 360:679-691.
11. Iguchi K., Matsunaga S., Nakano T., Usui S., Hirano K. Inhibition of caveolin-1 expression by incadronate in PC-3 prostate cells. Anticancer Res. 2006, 26:2977-2981.
12. Iguchi K., Nakano T., Usui S., Hirano K. Incadronate inhibits aminopeptidase N expression in prostatic PC-3 cells. Cancer Lett. 2006, 237:223-233.
13. Iguchi K., Tatsuda Y., Usui S., Hirano K. Pamidronate down-regulates urokinase-type plasminogen activator expression in PC-3 prostate cancer cells. Anticancer Res. 2007, 27:3843-3848.
14. Inoue R., Matsuki N.A., Jing G., Kanematsu T., Abe K., Hirata M. The inhibitory effect of alendronate, a nitrogen-containing bisphosphonate on the PI3K-Akt-NF?B pathway in osteosarcoma cells. Br. J. Pharmacol. 2005, 146:633-641.
15. Kang M.H., Reynolds C.P. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin. Cancer Res. 2009, 15:1126-1132.
16. Kim S.J., Uehara H., Yazici S., He J., Langley R.R., Mathew P., Fan D., Fidler I.J. Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer. Cancer Res. 2005, 65:3707-3715.
17. Lee M.V., Fong E.M., Singer F.R., Guenette R.S. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res. 2001, 61:2602-2608.
18. Li D., Ueta E., Kimura T., Yamamoto T., Osaki T. Reactive oxygen species (ROS) control the expression of Bcl-2 family proteins by regulating their phosphorylation and ubiquitination. Cancer Sci. 2004, 95:644-650.
19. Liu G., Kelly W.K., Wilding G., Leopold L., Brill K., Somer B. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin. Cancer Res. 2009, 15:3172-3176.
20. Lu S., Zhang J., Zhou Z., Liao M.L., He W.Z., Zhou X.Y., Li Z.M., Xiang J.Q., Wang J.J., Chen H.Q. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice. Oncol. Rep. 2008, 20:581-587.
21. Mazzocca A., Giusti S., Hamilton A.D., Sebti S.M., Pantaleo P., Carloni V. Growth inhibition by the farnesyltransferase inhibitor FTI-277 involves Bcl-2 expression and defective association with Raf-1 in liver cancer cell lines. Mol. Pharmacol. 2003, 63:159-166.
22. McDonnell T.J., Troncoso P., Brisbay S.M., Logothetis C., Chung L.W., Hsieh J.T., Tu S.M., Campbell M.L. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 1992, 52:6940-6944.
23. Nishida S., Fujii Y., Yoshioka S., Kikuichi S., Tsubaki M., Irimajiri K. A new bisphosphonate, YM529 induces apoptosis in HL60 cells by decreasing phosphorylation of single survival signal ERK. Life Sci. 2003, 73:2655-2664.
24. Oades G.M., Senaratne S.G., Clarke I.A., Kirby R.S., Colston K.W. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J. Urol. 2003, 170:246-252.
25. Ory B., Blanchard F., Battaglia S., Gouin F., Redini F., Heymann D. Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status. Mol. Pharmacol. 2007, 71:333-343.
26. Pugazhenthi S., Nesterova A., Sable C., Heidenreich K.A., Boxer L.M., Heasley L.E., Reusch J.E. Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J. Biol. Chem. 2000, 275:10,761-10,766.
27. Raaijmakers J.H., Bos J.L. Specificity in Ras and Rap signaling. J. Biol. Chem. 2009, 284:10,995-10,999.
28. Russell R.G., Xia Z., Dunford J.E., Oppermann U., Kwaasi A., Hulley P.A., Kavanagh K.L., Triffitt J.T., Lundy M.W., Phipps R.J., Barnett B.L., Coxon F.P., Rogers M.J., Watts N.B., Ebetino F.H. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann. NY Acad. Sci. 2007, 1117:209-257.
29. Sato M., Grasser W., Endo N., Akins R., Simmons H., Thompson D.D., Golub E., Rodan G.A. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J. Clin. Invest. 1991, 88:2095-2105.
30. Senaratne S.G., Pirianov G., Mansi J.L., Arnett T.R., Colston K.W. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br. J. Cancer 2000, 82:1459-1468.
31. Smith M.R., McGovern F.J., Zietman A.L., Fallon M.A., Hayden D.L., Schoenfeld D.A., Kantoff P.W., Finkelstein J.S. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J. Med. 2001, 345:948-955.
32. Tatsuda Y., Iguchi K., Usui S., Suzui M., Hirano K. Protein kinase C is inhibited by bisphosphonates in prostate cancer PC-3 cells. Eur. J. Pharmacol. 2010, 627:348-353.
33. Taylor D., Badiani P., Weston K. A dominant interfering Myb mutant causes apoptosis in T cells. Genes Dev. 1996, 10:2732-2744.
34. Valenti M.T., Bertoldo F., Dalle Carbonare L., Azzarello G., Zenari S., Zanatta M., Balducci E., Vinante O., Lo Cascio V. The effect of bisphosphonates on gene expression: GAPDH as a housekeeping or a new target gene?. BMC Cancer 2006, 6:49.
35. Virtanen S.S., Vaananen H.K., Harkonen P.L., Lakkakorpi P.T. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res. 2002, 62:2708-2714.
36. Walker K., Olson M.F. Targeting Ras and Rho GTPases as opportunities for cancer therapeutics. Curr. Opin. Genet. Dev. 2005, 15:62-68.
37. Wang L., Liu F., Adamo M.L. Cyclic AMP inhibits extracellular signal-regulated kinase and phosphatidylinositol 3-kinase/Akt pathways by inhibiting Rap1. J. Biol. Chem. 2001, 276:37,242-37,249.
38. Wang C.X., Song J.H., Song D.K., Yong V.W., Shuaib A., Hao C. Cyclin-dependent kinase-5 prevents neuronal apoptosis through ERK-mediated upregulation of Bcl-2. Cell Death Differ. 2006, 13:1203-1212.
39. Wang L., Sloper D.T., Addo S.N., Tian D., Slaton J.W., Xing C. WL-276, an antagonist against Bcl-2 proteins, overcomes drug resistance and suppresses prostate tumor growth. Cancer Res. 2008, 68:4377-4383.
40. Yip K.W., Reed J.C. Bcl-2 family proteins and cancer. Oncogene 2008, 27:6398-6406.